Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, window of opportunity platform study in patients with
muscle-invasive bladder cancer (MIBC) deemed ineligible to receive cisplatin-based
neoadjuvant chemotherapy, who are scheduled to undergo definitive surgery (radical
cystectomy). The primary objective of this study is to assess changes to immunogenomic
markers after treatment with pembrolizumab alone and in combination with the selective class
I histone deacetylase (HDAC) inhibitor (entinostat).